ArthroCare's Quiet Stock Ride
This article was originally published in Start Up
ArthroCare's stock is soaring. Following a series of favorable announcements by the company, its price has risen steadily over the past several months, reaching a high of $72.50 on October 29. Arthrocare's most important announcement concerned the settlement of its patent litigation with Johnson & Johnson.
You may also be interested in...
A business development panel representing the emerging group of mid-sized device dealmakers that are actively looking for innovative technology from small companies discusses the current state of medtech dealmaking.
In Vivo continues its series of interviewing device company executives. This time, we pick from a category that might be called "the young Turks": executives from the younger generation who are running the next-generation of major medical device companies, those that will rival if not replace the Medtronics and Guidants of the past generation. Having cut his teeth at device giant Medtronic, Mike Baker has spent the last 10 years running ArthroCare, one of the industry's next-generation leaders.
Ten years ago, ArthroCare was just one of dozens of small medical device start-ups to have gone public in the IPO boom of 1995 and 1996. But while most of ArthroCare's classmates in what has come to be known as the Class of '96 have disappeared, ArthroCare is a fast-growing, self-sustaining public company. Its core technology-a radio-frequency-based ablation tool called Coblation--results in faster healing times, with a fraction of the pain of other modalities that remove tissue. It has thus been picked up by a number of physican specialities including ENT surgeons and orthopedic surgeons, and for a large number of applications. ArthroCare now faces a host of new challenges, most notably, how to continue to capitalize and build on its proprietary plasma-mediated technology and, in the process, how to sustain that growth and the share price rewards that come with it.